Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

News Room

News Room Search
News Room List
NO Title Date Viewers
39 HL161 (batoclimab) Demonstrated Positive Top-line Results in Phase 2 Clinical Trial in Myasthenia Gravis 2020-08-26 310
38 HanAll Biopharma recorded KRW 22.6 billion and KRW 1.6 billion in sales and operating income for the second quarter 2020-07-29 209
37 HanAll Biopharma Appoints Seung-won Jeong as CEO of HPI, HanAll’s US Subsidiary 2020-06-04 231
36 HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients 2020-04-22 186
35 Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED 2020-03-31 181
34 HanAll Biopharma Recorded Its Record-High Earnings Last Year 2020-02-27 182
33 HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3 (VELOS-2) Study at a Press Conference 2020-01-28 3612
32 HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease 2019-03-12 4116
31 HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S. 2018-10-29 3611
30 HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China 2018-10-01 3878
1 2 현재 페이지3 4 5 6